Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $78 price target The company’s lead asset, TTI-101, which is being assessed in the Phase 2 REVERT-IPF trial with data in Q4, is positioned to drive broad improvement with an optimal profile, the analyst tells investors in a research note. The firm says the drug is a “differentiated” STAT3 inhibitor small molecule with non-covalent bonding uniquely positioning it to specifically target canonical nuclear function with no mitochondrial effect.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Tvardi Therapeutics Updates Corporate Presentation on Therapies
- Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
- Tvardi Therapeutics files to sell 2.08M shares of common stock for holders
- Buy Rating for Tvardi Therapeutics Driven by Promising Phase 2 Trial Results and Growth Potential
- Tvardi Therapeutics completes enrollment in TTI-101 trial